Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.

Daniel Vargas P de AlmeidaJustine M AndersonDaniel C DanilaMichael J MorrisSusan F SlovinWassim AbidaErica D CohnRaymond E BaserHoward I ScherKaren A Autio

Published in: Journal of immunotherapy and precision oncology (2023)

PRO-CTCAEs focused on irAEs capture the patient's immunotherapy experience while complementing the clinician's toxicity assessment measures. Further study is needed to assess PRO-CTCAE's utility in identifying and managing irAEs.

Keyphrases

phase ii study
prostate cancer
anti inflammatory

open label
locally advanced
radical prostatectomy

case report
oxidative stress

squamous cell carcinoma
radiation therapy